LENSAR Inc. Third Quarter 2026 Results Conference Call - LENSAR INC

Explicit Guidance:

• Cash Flow & Liquidity: Anticipates approximately $2 million in cash burn for the remainder of 2026 due to inventory investment and Alcon transaction fees; expects the company to approach break-even at an unspecified point in 2027.
• Margins: Expects Gross Margin of ~80% for Procedure Revenue; notes that the Q3 58% gross margin was a temporary anomaly driven by low service costs and revenue mix, not expected to repeat.
• Capital Allocation: The Q3 $10 million revolving line of credit provides liquidity for continued equipment placements.

Business-Segment Outlook:

• Installed Base & Sales: Plans to ramp distribution in International Outside US (OUS) markets, expecting robust business delivery in mid-2027.
• Procedure Volume: Expects a 15–20% increase in procedure volume per site following migration to the Ally system once surgeons are fully trained and comfortable.
• Recurring Revenue: Anticipates continued growth in recurring revenue as the installed base expands and utilization increases, with OUS redeployment of legacy units expected to accelerate installation rates in international markets.
• Backlog: Ended Q3 2026 with 12 Ally systems in backlog awaiting installation.

Market and Competitive Outlook:

• Demand Trends: Views the broader cataract market volume as slightly down, but expects physician focus to shift toward "advanced technology procedures" due to reimbursement pressures, benefiting Ally.
• Competitive Dynamics: Anticipates capturing share from both existing femtosecond users and "femtosecond-naive" surgeons.
• Reimbursement: Notes recent reimbursement changes in Germany and Switzerland initially slowed activity but expects strong recovery in those markets moving forward.
• Market Share: Targeting continued expansion in the US (dominant market) and OUS (currently a "work in progress").

Macro / Industry Outlook:

• Geography: US market is "work in progress" for migration but currently leads in volume; OUS recovery is tied to distributor re-engagement and post-holiday seasonality.
• Regulatory/Reimbursement: Monitoring reimbursement dynamics which are driving the shift toward higher-value advanced technology procedures.

Strategic Initiatives:

• Product Launches:
  • Robotic Docking: Anticipated introduction by the end of Q1 2027 (potentially early Q2) for fully automated system location and docking.
  • Corneal Capabilities: Development underway to add corneal-based procedures (flaps, LASIK, incisions), requiring a new Patient Interface Device (PID); timeline not explicitly specified but ongoing.
  • FemtoPhaco Integration: If a strategic partner is identified, the integration of phacoemulsification is expected within 18 months to less than two years.
  • Other Integrations: Exploring integration of operating microscopes and other laser modalities for a "workstation" approach; these are 3–5 year horizon projects.
• Commercial: Re-engaging international distributors; focusing on education and training to drive adoption.

Risks and Headwinds to Outlook:

• Seasonality: Q4 and Q1 historically subject to seasonality; Q4 2025 system sales were unusually high, making Q3 2026 comparisons difficult.
• External Disruptions: Previous slowdown attributed to the Alcon transaction uncertainty, summer holidays, and reimbursement changes in Europe.
• Market Conditions: Overall cataract surgery volume is currently "down slightly," the first time in history the speaker has observed this.
• Execution Risk: OUS market ramp-up depends on successfully re-activating distributor relationships; margin guidance assumes normal service cost activity, which may fluctuate.

Management Tone on the Future:

• Confidence Level: "Optimistic" and "Confident" regarding the team, technology, and direction.
• Narrative: Emphasizes the transition from a "work in progress" to a "durable business" driven by recurring revenue and practice integration.
• Guidance vs. Prior: Highlights a shift from capital sales volatility to recurring revenue growth (89% of Q3 revenue) and improved gross margins (58% vs 42% prior year).

Miscellaneous:

• Liquidity: Secured a $10 million revolving line of credit in Q3, increasing total available liquidity to $22.6 million as of September 30, 2026.
• Installed Base: Global Ally installed base is ~225 systems; total laser installed base is ~450 systems.
• Adoption: 42% of installs in the last 12 months were with surgeons previously not using lasers.